CLINICAL, SUBCLINICAL CHARACTERISTICS AND TREATMENT RESULTS OF CERVICAL CANCER STAGE IIB – IIIB BY HEMORADIOTHERAPY AT CAN THO ONCOLOGY HOSPITAL IN 2019-2020
Main Article Content
Abstract
Background: Chemoradiotherapy is the main treatment for patients with stage IIB- IIIB cervical cancer. This study evaluates the result of chemoradiotherapy in the treatment of stage IIB- IIIB cervical cancer. Objectives: To characterize clinical, subclinical and to dertermine response rates and side effects and analysis of several associated factors in the patients with stage IIB- IIIB cervical cancer receiving chemoradiotherapy. Materials and methods: During the study period January 2019 to June 2020, we collected 51 cases meeting the sample selection criteria at the Can Tho Oncology Hospital. Results: The average age is 55 ± 8, the average size is 4.2± 1,1cm and there are 70.6% of large size tumors (> 4cm), papilloma macroscopic tumors usually account for 62.7%, papillary carcinoma accounting for 84.2%, stage IIB accounts for 52.9% and stage IIIB accounts for 45.1%, rate of pelvic lymph node metastasis is 33.3%, hydronephrosis is 5.9%. After 3 months of chemotherapy, the complete response after 3 months is 88.2%, the complete response after 6 months is 85.1%, the rate of metastatic progression disease accounts for 14.9%. The most common side effect is vaginitis, which accounts for 76.5%. Conclusion: The treatment of stage IIB- IIIB cervical cancer by chemoradiotherapy is a highly effective treatment with acceptable side effects.
Keywords
Cervical cancer, cervical cancer stage IIB- IIIB, chemoradiotherapy
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
2. Trần Đặng Ngọc Linh (2013), Hiệu quả xạ trị trong ung thư cổ tử cung giai đoạn IIB- IIIB, Luận án tiến sĩ y học. Trường đại học Y thành phố HCM>
3. Trần Thanh Phong (2015), Đánh giá bước đầu điều trị ung thư cổ tử cung giai đoạn IIB- IVA bằng xạ trị ngoài phối hợp xạ trị áp sát suất liều cao tại Bệnh viện Ung Bướu Cần Thơ, Tạp chí Ung thư học Việt Nam, 3, tr. 231-234.
4. Huỳnh Quyết Thắng, Hồ Long Hiển (2013), Kết quả ghi nhận ung thư tại Cần Thơ năm 2005- 2011, Khoa học Y Dược, 33, tr. 75-83.
5. Ngô Thị Tính (2006), Đánh giá kết quả điều trị sớm ung thư cổ tử cung giai đoạn IIB- IIIB tại Bệnh viện K từ tháng 9/2003 đến tháng 9/2005, Thông tin y dược, 3, tr. 29-32.
6. Cetina L. (2006), Routine management of locally advanced cervical cancer with concurrent radiation and cisplatin. Five years result, BMC Women’s Health, 6(3), pp. 1-7.
7. Globocan (2018), Estimated cancer incidence, mortality and prevalence in wordwide in 2018. http://gco.iarc.fr .
8. Noha J. (2016), A volumetric analysis of GTV and CTV as defined by the GEC- ESTRO recommendations in FIGO stage IIB- IIIB cervical cancer patients treated with IGABT ain a prospective multicentric trial (EMBRACE), Radiotherapy and Oncology, 120, pp. 404- 411.
9. Nam E. J. (2013), Comparison of carboplatin and cisplatin based concurrent chemoradiotherapy in locally advanced cervical cancer patients with morbidity risks, Gynecologic Oncology, 18, pp. 843-849.
10. Kenji Y. (2015), Assessment of parametrial by growth pattern in patients with FIGO stage IIB and IIIB cervical cancer: analysis of patients from a prospective multicentric trial (EMBRACE), International Journal of Radiation Oncology, 1, pp. 1- 22.
11. Tae Eung K. (2012), Outcomes and prognostic factors of cervical cancer after concurrent chemoradiation, Obstetrics and Gynaecology Research, 38 (11), pp. 1315-1320.
12. Sirák I. (2008), The influence of cisplatin dose upon survival in concurrent chemoradiotherapy of locally advanced cervical carcinoma with weekly cisplatin, Acta Medica, 51(2), pp. 95-99.